A. O. Donnell, A. Padhani, C. Hayes, A. J. Kakkar, M. Leach, J. M. Trigo, M. Scurr, F. Raynaud, S. Phillips, W. Aherne, A. Hardcastle, P. Workman, A. Hannah and I. Judson, “A Phase I Study of the Angiogenesis Inhibitor SU5416 (Semaxanib) in Solid Tumors, Incorporating Dynamic Contrast MR Pharmacodynamic End Points,” British Journal of Cancer, Vol. 93, No. 8, 2005, pp. 876-883. doi:10.1038/sj.bjc.6602797

has been cited by the following article:

• TITLE: Indolin-2-Ones in Clinical Trials as Potential Kinase Inhibitors: A Review

  AUTHORS: Chinnasamy Rajaram Prakash, Panneerselvam Theivendren, Sundararajan Raja

  KEYWORDS: Isatin; Enzyme Inhibition; Anticancer

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.3 No.1, January 12, 2012

  ABSTRACT: The kinases have been intensely studied because of their involvement in regulating essential cellular activation of signaling cascades in response to extracellular and intracellular stimuli to control cell growth, proliferation, and survival. Recent cancer genomic sequencing studies have revealed that many more kinases contribute to tumor genesis and are potential targets for inhibitor drug development intervention. Herein we review recent results that have helped to unravel the indolin-2-ones underlying the confiicting roles of the kinase inhibition regulation. This review focuses on the potential of kinases as a chemotherapeutic target in cancer treatment and highlights important recent advances in the development of indolin-2-ones as kinase inhibitors.